Biotech News

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Outset Medical (OM)Outset Medical2026-07-02 20:05 ESTCompany update

SAN JOSE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of

Open original release

Related news

OMOutset Medical2026-06-25 13:46 EST

Outset Medical to Present at RBC Global Healthcare Conference

OMOutset Medical2026-06-25 13:46 EST

Outset Medical Reports First-Quarter Results

OMOutset Medical2026-06-25 13:46 EST

New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System

OMOutset Medical2026-06-25 13:46 EST

Outset Medical Reports Third-Quarter Results

OMOutset Medical2026-06-25 13:46 EST

Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

OMOutset Medical2026-06-25 13:46 EST

Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

OMOutset Medical2026-06-25 13:46 EST

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

OMOutset Medical2026-06-25 13:46 EST

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

OMOutset Medical2026-06-25 13:46 EST

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results

OMOutset Medical2026-06-25 13:46 EST

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

View all latest news

Outset Medical

Outset Medical is a medical devices company focused on product adoption, procedure volume, and how clinical workflow converts into recurring demand.

Recent company news

OMZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

OMZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

OMBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

OMGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

OMMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 4.36 USD
Market cap: 82.12M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States